TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01258452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074
Description: Drug is administered to subject in a fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5974
Description: Drug is administered to subject after consumption of a high fat, high calorie meal
Study: NCT03785652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005 extended-release tablets 40 mg
Description: LY03005 extended-release tablets 40 mg group :40mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfas

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005 extended-release tablets 80 mg group
Description: LY03005 extended-release tablets 80 mg group :~80mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005 extended-release tablets 120 mg group
Description: LY03005 extended-release tablets 120 mg group :~120mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005 extended-release tablets 160 mg group
Description: LY03005 extended-release tablets 160 mg group :~160mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo group :~Placebo ，orally once a day, at a regular morning time on an empty stomach or after breakfast
Study: NCT03130855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inferior alveolar nerve block with 4% articaine
Description: an anesthetic technique using 4% articaine anesthetic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buccal infiltration with 4% articaine
Description: anesthetic technique using 4% articaine anesthetic solution
Study: NCT00722007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cormet Hip Resurfacing
Description: Cormet Hip Resurfacing implant
Study: NCT02095210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiolabeled [68Ga]ABY-025
Description: Single dose of 100 μg ABY-025 labeled with 500 MBq gallium-68, administrated as a slow intravenous injection. All patients will receive the same dose.
Study: NCT03980561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Active medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive medication
Study: NCT00345826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Study: NCT02561728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hangar Helmet
Description: Child will be fitted with the Hangar Helmet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hangar Helmet
Description: Child will be fitted with the Hangar Helmet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P-Pod Helmet
Description: Child will be fitted with the P-Pod Helmet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P-Pod Helmet
Description: Child will be fitted with the P-Pod Helmet
Study: NCT03257774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adhesive strip A
Description: Strip consisting of a newly developed adhesive

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adhesive strip B
Description: Strip consisting of a newly developed adhesive

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adhesive strip C
Description: Strip consisting of a newly developed adhesive
Study: NCT02784002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridinilazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fidaxomicin
Study: NCT00170456

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rPA vaccine containing alhydrogel
Study: NCT03649126

Intervention type: BEHAVIORAL
Intervention: Implementation tools
Description: Implementation tools developed by experts in order to increase the use of SSR in pathology

Intervention type: BEHAVIORAL
Intervention: Implementation tools
Description: Implementation tools developed by experts in order to increase the use of SSR in pathology

Intervention type: BEHAVIORAL
Intervention: Implementation tools
Description: Implementation tools developed by experts in order to increase the use of SSR in pathology

Intervention type: BEHAVIORAL
Intervention: Implementation tools
Description: Implementation tools developed by experts in order to increase the use of SSR in pathology

Intervention type: BEHAVIORAL
Intervention: Implementation tools
Description: Implementation tools developed by experts in order to increase the use of SSR in pathology

Intervention type: BEHAVIORAL
Intervention: Implementation tools
Description: Implementation tools developed by experts in order to increase the use of SSR in pathology
Study: NCT00170456

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rPA vaccine containing alhydrogel

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rPA vaccine containing alhydrogel
Study: NCT05040412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: difficult laryngoscopy
Description: Patients will be intubated with the direct laryngoscope.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: difficult laryngoscopy
Description: Patients will be intubated with the direct laryngoscope.
Study: NCT00765245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Orally once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 20 mg daily, Days 1-21, followed by 7 days rest (28-day cycle). Cycles will be repeated every 28 days for a total of 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 intravenously (IV) starting on Day 8, Cycle 1 of lenalidomide. Rituximab will be repeated on Day 8 of odd numbered cycles (Cycles 1, 3, 5, 7, 9, and 11) for a total of 6 doses from randomization.
Study: NCT00281827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Day 1 of Cycles 1, 2 and 3 - intravenously (IV) 30 minutes (Area Under the Curve = 5.5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Days 1 and 8 of Cycles 1, 2 and 3 - 30 minute IV, 1000 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Oral administration: Cycle 1 - Day 1 50 mg, Day 2 100 mg, Day 3 150 mg, Day 4 and continuing until end of study treatment 200 mg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Resection - between 2 and 6 weeks following last dose of chemotherapy.
Study: NCT03026868

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quadrilateral surface plate
Description: Both anterior and posterior approaches were always conducted to manage the fragments of quadrilateral surface. Novel quadrilateral surface plate was used in this study to examine whether the fragments could be fixed through single Stoppa approach.
Study: NCT03519152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose diclofenac
Description: it is a split mouth design in which one side recieved low dose diclofenac(25mg) after periodontal flap surgery and in next week second side will recieve diclofenac 50mg after flap surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: low dose diclofenac
Description: it is a split mouth design in which one side recieved low dose diclofenac(25mg) after periodontal flap surgery and in next week second side will recieve diclofenac 50mg after flap surgery.
Study: NCT01666067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vytorin
Study: NCT01070927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4929097
Description: 80mg po daily, 3 days on 4 days off schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4929097
Description: recommended phaseII dose, orally once daily, 3 days on 4 days off schedule
Study: NCT04382326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20-valent pneumococcal conjugate vaccine
Description: 20-valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 13-valent pneumococcal conjugate vaccine
Study: NCT01326520

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: milk phospholipid
Description: The patients will consume daily 250 mL of a dairy product, which is enriched with 3 g of milk phospholipids.
Study: NCT01666067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Study: NCT02267759

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath videolaryngoscopy
Description: After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, McGrath videolaryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
Study: NCT01326520

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: diary product
Description: The patients will consume daily 250 mL of a common dairy product.
Study: NCT01569334

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood samples

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood samples

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood samples
Study: NCT02267759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscopy
Description: After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, Macintosh laryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
Study: NCT01887366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-1380 150 mg
Description: Subjects assigned to TV-1380 150 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. The injection volume will be the same for all treatment groups. Therefore, to accommodate the volume required for the highest dosing group (3.0 mL), subjects in this group will receive 3.0 mL IM injection of TV-1380 150 mg (1.5 mL TV-1380 and 1.5 mL placebo/diluents).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-1380 300 mg
Description: Subjects assigned to TV-1380 300 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL TV-1380.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects assigned to placebo will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL placebo.
Study: NCT01264861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide
Description: Safinamide 100 mg/day = two 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 200 mg/day = four 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 150 mg = three 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 300 mg/day = six 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 250 mg = five 50 mg tablets administered orally, once a day, in the morning, with or without food.
Study: NCT02250885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selective Inhibitor fo Nuclear Export (SINE)
Study: NCT00672438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Description: Target controlled intravenous infusion of alfentanil at a plasma concentration of 100ng/ml

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo infusion
Description: Intravenous infusion of normal saline
Study: NCT03915548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Behavioral Activation/ Problem Solving Intervention
Description: The interventionist presents the rationale for BA/PS, promotes a positive problem orientation, and educates about the framework for problem-solving and action planning. The interventionist then administers the Canadian Occupational Performance Measure to elicit participant priorities, motivation, and long-term goals. The interventionist then guides the participant in using the BA/PS framework to set a goal, brainstorm solutions to challenges, and create a detailed action plan for the coming week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Condition
Description: The interventionist provides education regarding nine cancer survivorship topics (i.e., healthy diets, physical activity, lymphedema management, smoking cessation, stress management, communication with providers, body image and sexuality, communication with social supports, work accommodations) during the control telephone contacts.
Study: NCT03398993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: 50 mg twice daily from3rd day of cycle till 7th day of cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: 50 mg twice daily from3rd day of cycle till 7th day of cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: 75 IU dail;y from 6th day of cycle till 8th of cycle once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: 75 IU dail;y from 6th day of cycle till 8th of cycle once daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial scratch
Description: The procedure was carried out in preovulatory day (known when dominant follicle reached 18_20 mm in diameter), usually, done around day 14-day of the cycle.~In the theatre, Patients put in a lithotomy position, sterilization was performed with the presence of good source of light., the procedure was carried out using a thin pipelle tube as follow :- A cuscoe's speculum was inserted into the vagina in order to visualize the cervix.~Cervix was grasped by vollselum upwards backwards, then pipelle tube passed through the cervix and uterine cavity, then moved up and down to make a single induced scratch two times in the lining endometrium of posterior wall of uterus.~The procedure took approximately 15minutes to complete
Study: NCT03669081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin was administered orally: 75 mg 30 minutes prior to operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule was administered orally 30 minutes prior to operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.
Study: NCT00812812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine 10mg tablet
Description: 1 or 2 tablet(s) once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine 20mg tablet
Description: 1 tablet once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matched placebo to paroxetine 10mg
Description: 2 tablets once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo to paroxetine 10mg
Description: 2 tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matched placebo to paroxetine 20mg
Description: 1 tablet once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo to paroxetine 20mg
Description: 1 tablet once a day
Study: NCT01401530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denileukin diftitox (E7777)
Description: E7777 will be administered by intravenous (IV) infusion for 5 days from Day 1 through 5 of each cycle (21 days/cycle) with 8 cycles in maximum for E7777 alone therapy. E7777 dose will be escalated from 6 micro-g/kg/day to 12, 15 and then to 18 in a stepwise fashion.
Study: NCT04462796

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium Citrate
Description: Magnesium Citrate 200 mg daily
Study: NCT01699425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ajust sling

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classical transobturator sling
Description: Control group
Study: NCT03169140

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TheraBand Kinesiology Tape
Description: A 20 cm strip of tape will be applied to each side of the low back directly over the erector spinae muscles at the site of pain. This tape will remain there, and be reapplied when necessary, for one week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TheraBand Kinesiology Tape
Description: A 20 cm strip of tape will be applied to each side of the low back directly over the erector spinae muscles at the site of pain. This tape will remain there, and be reapplied when necessary, for one week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofreeze
Description: The topical analgesic will be sprayed directly on top of the erector spinae and site of pain low back directly, from inferior to superior to inferior 4 times a day for one week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofreeze
Description: The topical analgesic will be sprayed directly on top of the erector spinae and site of pain low back directly, from inferior to superior to inferior 4 times a day for one week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice
Description: An at-home pain management care sheet, outlining standard care advice will be followed for at home pain management for one week.
Study: NCT01046110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected under the skin once daily for 26 weeks. The doses will be individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: Sitagliptin tablets administered orally once a day at the same time every day for 26 weeks
Study: NCT04087057

Intervention type: OTHER
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Patients' medical records are reviewed

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Complete questionnaires
Study: NCT03542643

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3 Polyunsaturated fatty acid
Description: 1g of Eicosapentaenoic acid (EPA)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive oil ethyl esters
Study: NCT04205279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Treadmill training
Description: Participants will be given thirteen slips and thirteen trips in stance and walking, followed by two slips and two trips at a higher intensity (posttest). Subjects would be consented if they would like to undergo fMRI pre and post-training. Participants not willing to undergo imaging would not be excluded. Three day training consisting of blocks of five consecutive gait-slips at varying intensities will be provided. Individuals with stroke would undergo an additional session (total 4 training sessions over 4 weeks (1session/week) since these individuals get easily fatigued and also might need more training sessions with sufficient rest interval to induce reactive adaptation. Training at a specific level will persist until the subjects show a recovery step response in at least 3/5 trials in a single block. Once subjects successfully adapt to this level, the perturbation intensity will be increased until they show a recovery response in at least 3/5 trials.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Overground training
Description: Slips and trips could be induced under either of the limbs. The specialized walkway consists of two sliding platforms, each of which is mounted on two rows of low friction linear bearings (friction coefficient = 0.02). The base plate of each platform is bolted separately onto the top of a force platform embedded in the floor. An electronic-mechanical latch system is used to control the 2 states of the support platform; that is, the locked state for regular walking and the release state to initiate slipping are carefully controlled. The sliding top of the platform is released after the heel strike (vertical force to exceed 2% of the body weight). The slip distance would be adjusted between 30 to 60 centimeters depending upon the different population and their physical capacity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Surefooted training
Description: During the first minute of each block, subjects would experience no perturbations followed by 3 minutes of single or multi-directional perturbations. A one minute break between each condition would be provided. Subject's fatigue would be assessed by Fatigue severity scale to determine the tolerability of 30 minute training protocol. The expected duration to complete the test would be a maximum of 1 hour including the preparation and training time.
Study: NCT02275897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Slow Speed of spinal injection
Description: Speed of injection over 60 seconds

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast Speed of spinal injection
Description: Speed of injection over 15 seconds
Study: NCT00718042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay
Description: Test blood donor sample with ABBOTT PRISM Chagas assay. If results are reactive, donor sample will be tested with Chagas Confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay
Description: Test blood donor sample with investigational Chagas assay. If results are reactive, donor samples will be tested with Chagas confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
Study: NCT03135223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-created intervention to promote physical activity
Description: A working group of girls and researcher co-created a school-specific intervention to promote physical activity
Study: NCT00304070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV